Literature DB >> 30921790

Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.

Kevin D Burns1, David Cherney2,3,4.   

Abstract

Entities:  

Year:  2019        PMID： 30921790     DOI： 10.1159/000499598

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


× No keyword cloud information.
  5 in total

1.  Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.

Authors:  Ryousuke Satou; Michael W Cypress; T Cooper Woods; Akemi Katsurada; Courtney M Dugas; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-04

Review 2.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

3.  Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.

Authors:  Martin Ho Yin Yeung; Ka Long Leung; Lai Yuen Choi; Jung Sun Yoo; Susan Yung; Pui-Kin So; Chi-Ming Wong
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 4.  Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.

Authors:  Victor Chien-Chia Wu; Yan-Rong Li; Chao-Yung Wang
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

5.  The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.

Authors:  Coenraad Withaar; Laura M G Meems; George Markousis-Mavrogenis; Cornelis J Boogerd; Herman H W Silljé; Elisabeth M Schouten; Martin M Dokter; Adriaan A Voors; B Daan Westenbrink; Carolyn S P Lam; Rudolf A de Boer
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.